Amanote Research
Register
Sign In
Clinical Biomarkers in Resectable NSCLC
Thorax
- United Kingdom
doi 10.1136/thx.2010.145532
Full Text
Open PDF
Abstract
Available in
full text
Categories
Pulmonary
Respiratory Medicine
Date
August 1, 2010
Authors
B. Khan
Publisher
BMJ
Related search
A Systematic Review and Meta-Analysis of Prognostic Biomarkers in Resectable Esophageal Adenocarcinomas
Scientific Reports
Multidisciplinary
P3.17-22 Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Clinical Analysis of the Resectable Gastric Cancer in the Cardiac Region.
Japanese Journal of Gastroenterological Surgery
Surgery
Gastroenterology
MA04.09 Neoadjuvant Atezolizumab in Resectable Non-Small Cell Lung Cancer (NSCLC): Updated Results From a Multicenter Study (LCMC3)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
MA19.06 Blood Based Biomarkers: RNA, KRAS and PD-L1 Strongly Matching With Tissue and Showing Correlation With Clinical Responses in NSCLC Patient’s
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Preoperative Chemotherapy and Radiotherapy Concomitant to Cetuximab in Resectable Stage IIIB NSCLC: A Multicentre Phase 2 Trial (SAKK 16/08)
British Journal of Cancer
Cancer Research
Oncology
Optimizing the Clinical Utility of Biomarkers in Oncology: The NCCN Biomarkers Compendium
Archives of Pathology and Laboratory Medicine
Medicine
Forensic Medicine
Pathology
Medical Laboratory Technology
P2.17-27 IMpower030: Phase III Study Evaluating Neoadjuvant Treatment of Resectable Stage II-IIIB NSCLC With Atezolizumab + Chemotherapy
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Clinical Biomarkers and Biotechnology in Fertile Window
Interventions in Gynaecology and Women’s Healthcare
